Bernardo D'Onofrio

MD | Rheumatologist | @LUMC_Leiden | Arthritis enthusiast.

[The Journal of Rheumatology @jrheum]

Images in Rheumatology

Necrotizing Sarcoid Granulomatosis in a Patient With Systemic Sclerosis

📖 https://t.co/oXwkwDWcAj
@donofriobern @LopciEgesta

#necrotizingsarcoidgranulomatosis #systemicsclerosis

[Bernardo D'Onofrio @donofriobern]

The current best way to manage #RA - early diagnosis, treatment steered to target and rapid escalation to biologics - is still not enough to reduce the risk of becoming #D2T.

👉🏻 read our new full paper here:

https://t.co/nDO1iyli2n

[Bernardo D'Onofrio @donofriobern]

Refractory #RA is a challenging condition and includes both inflammatory and non-inflammatory phenotypes.

Is the #PGA really helpful in identifying non-inflammatory patients?

🔥 new insights from @LUMC_Leiden #EAC here:

https://t.co/C6tNxDpXI7…

[Bernardo D'Onofrio @donofriobern]

The recent #outbreak of #ParvovirusB19 in Europe puts the rheumatologists on the frontline. Are infected patients at higher risk of being #misclassified into a systemic rheumatic disease?

👉🏻 read the results of our report recently published in @RheumJnl

https://t.co/BU5ccBLKQR

[Bernardo D'Onofrio @donofriobern]

Only a minority of patients with #RA is able to achieve #remission. Could a better stratification of patients lead to better outcomes?

Here the results of our systematic literature #review.

https://t.co/AghItINDnK

[Bernardo D'Onofrio @donofriobern]

#beyond the science: many greetings from me and my dear colleagues and friends from #EULAR2024 🤍

@ReumaHumanitas
@HumanitasMilano
@eular_org

[Bernardo D'Onofrio @donofriobern]

Why and when #JAK inhibition might be useful in treating #psoriatic enthesitis?

We discuss about it in this latest Editorial on #Rheumatology @RheumatologyUK

https://t.co/XIB2R8XR8c

[Bernardo D'Onofrio @donofriobern]

@ReumaHumanitas @HumanitasMilano

[Pedro Machado @pedrommcmachado]

📢 Hot of the press! Latest @Official_ASAS publication reiterates pivotal consensus on #axSpA nomenclature: "axSpA" as the universal term; "r-axSpA" preferred to "AS". Next steps: consistent adoption in educational materials, manuscripts, presentations, ICD-coding integration.

[Bernardo D'Onofrio @donofriobern]

@Lollo7770 @CongressoSir 💓

[Bernardo D'Onofrio @donofriobern]

Autoantibody-positive and negative patients with early #rheumatoidarthritis have a similar chance to achieve and sustain Boolean #remission. However, they might differ in the mechanisms linked to Boolean remission unachievement and loss.

We talked about during @CongressoSir 2023

[Bernardo D'Onofrio @donofriobern]

Here my 3 posters at @CongressoSir 2023.

We talked about #nintedanib in myocardial fibrosis in #systemicsclerosis and prediction of response to treatment in #rheumatoidarthritis patients through a #SLR.

@SIRreumatologia
@SIRyoung_IT

[Bernardo D'Onofrio @donofriobern]

All’improvviso Juri Chechi.

@CongressoSir
@SIRreumatologia
@SIRyoung_IT

[Bernardo D'Onofrio @donofriobern]

Cerimonia di apertura del congresso nazionale #SIR 2023.

@CongressoSir

[Bernardo D'Onofrio @donofriobern]

@Lollo7770 @ern_reconnet Bel pensiero ❤️

[Artem Minalyan, MD, RhMSUS, DABOM @AMinalyan]

The CLASS project (#antisynthetase syndrome classification criteria): expected 2024: @docrota @Lollo7770
✅Jo-1 ab is the most 🎯 (other anti-synthetase abs (high false + and -)
✅anti-Ro52 and CYTOPLASMIC ANA are common
✅ Any form of ILD🫁
#ACR23
#rheumX
#pulmX
@ACRheum

[Bernardo D'Onofrio @donofriobern]

31/10/2023: I’m officially a rheumatologist!
@unipv

[Bernardo D'Onofrio @donofriobern]

@MaxKonigMD @Lollo7770

[ClaB @cb4680]

An Italian university is offering a 1-year research contract for 19,400 euros, post-doc preferred. That's actually a standard remuneration for this kind of contracts in Italy. No wonder you find so many Italian researchers outside of Italy.